Table 1.
Examples of biologics for inflammatory bowel disease, approved and under development
| Name | Primary target | FDA-approved indication |
|---|---|---|
| Infliximab (Remicade®) | TNF | CD, UC |
| Adalimumab (Humira®) | TNF | CD, UC |
| Certolizumab (Cimzia®) | TNF | CD |
| Golimumab (Simponi®) | TNF | UC |
| Natalizumab (Tysabri®) | alpha-4 integrin | CD |
| Vedolizumab (Entyvio®) | alpha-4-beta-7 integrin | CD, UC |
| Ustekinumab (Stelara®) | IL-12/23 | N/A |
| Etrolizumab | beta-7 integrin | N/A |
| Anrukinzumab | IL-13 | N/A |
FDA = Food and Drug Administration; TNF = tumor necrosis factor; IL = interleukin; CD = Crohn’s disease; UC = ulcerative colitis; N/A = not available